Mineralys Therapeutics
A private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.
The USA-based company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101.
This drug, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.
In June 2022, Mineralys announced the completion of an oversubscribed and up-sized $118 million Series B financing.
Latest Mineralys Therapeutics News & Features
12 February 2024
13 February 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze